Literature DB >> 33363946

Dengue fever complicated by hemophagocytic lymphohistiocytosis: Report of 2 cases and bone marrow findings.

Chee Yik Chang1, Mahaletchumi Rajappan1, Masliza Zaid1, Edmund L C Ong2.   

Abstract

Hemophagocytic lymphohistiocytosis is a rare but severe complication of dengue infection which carries a high mortality. This report highlights the importance of early recognition of this condition as prompt appropriate treatment improves outcomes.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow biopsy; dengue fever; hemophagocytic lymphohistiocytosis; severe dengue

Year:  2020        PMID: 33363946      PMCID: PMC7752383          DOI: 10.1002/ccr3.3422

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

Hemophagocytic lymphohistiocytosis (HLH) is a potentially life‐threatening condition, characterized by hyperinflammation due to the uncontrolled proliferation of activated lymphocytes and histiocytes secreting large amounts of inflammatory cytokines. HLH is classified into primary (genetic) or secondary (acquired). The latter is usually caused by viral infection, autoimmune disease, or neoplastic condition. Epstein‐Barr virus (EBV) is recognized to be one of the most common cause of infection‐associated HLH and is associated with a poor outcome. Infection with the dengue virus is increasingly recognized as an important cause of secondary HLH. Severe infection is associated with a high mortality and in those who developed secondary HLH may be as high as 43%. Severe dengue infection complicated by HLH may require interventions such as systemic corticosteroids, intravenous immunoglobulin, or chemotherapy. Here, we report 2 cases of dengue‐associated HLH with good outcomes following prompt diagnosis and treatment.

CASE 1

A previously well, 33‐year‐old male presented on day 2 of illness with fever, myalgia, and headache. He had a past history of dengue infection 5 years ago. Clinically, he was hemodynamically stable and well hydrated. Acute dengue infection was confirmed by positive NS‐1 antigen assay (SD Bioline Dengue Duo kit). In the ward, he received intravenous fluid and symptomatic treatment. There was no evidence of plasma leakage or hypotensive episode throughout the hospitalization. His blood pressure ranged from 110‐130 mm Hg (systolic) and 60‐75 mm Hg (diastolic), and the heart rate was ranging between 70 and 85 beats per minute. There was no evidence of organomegaly on physical examination. His fever recurred on the 4th hospital day (day 5 of illness) with temperature recorded at 39.6°C after an initial defervescence (Figure 1). Further investigations showed platelet count of 60 × 109/L with an increasing triglycerides and decreasing fibrinogen. The serum ferritin was raised at 8364mcg/L (Table 1). Serial blood cultures were negative. A clinical suspicion of HLH was strongly considered as the HScore was 176 with HLH probability of 62%. A bone marrow examination was performed which showed a normocellular marrow with increased number of histiocytes, and evidence of hemophagocytosis (Figure 2).
Figure 1

Temperature trend of Case 1

Table 1

Laboratory results of Case 1

Day of illness
D2D3D4D5D6D7D8
Hemoglobin (g/L) [12‐15]13.512.81413.713.81513.9
Hematocrit [36‐46]37353838374038
White cell (×109/L) [4‐10]98.46.76.78.616.217
Platelet (×109/L) [150‐410]365210560114118190
ALT (U/L) [5‐33]12011510092737253
AST (U/L) [5‐32]9693909211010656
LDH (U/L) [135‐214]2402503686338531013531
Ferritin (μg/L) [13‐150]4295836414 98517 4929185
Fibrinogen (g/L) [2.2‐3.9]2.62.32.62.52.0
Triglyceride (mmol/L) [1.7‐2.3]1.42.11.72.82.4
Creatinine (μmol/L) [44‐80]77788287757463
Figure 2

Bone marrow aspirates examination showed a normocellular marrow with evidence of hemophagocytosis

Temperature trend of Case 1 Laboratory results of Case 1 Bone marrow aspirates examination showed a normocellular marrow with evidence of hemophagocytosis Intravenous dexamethasone at 10 mg/m2/d was started on receipt of the results (day 5 of patient's illness). The serum ferritin peaked on day 7 of illness (17492mcg/L) before falling on the following day (9185 mcg/L). He responded well to dexamethasone as evidenced by resolution of fever and recovery of blood counts with no evidence of organ dysfunction. As a result, dexamethasone was discontinued on day 8 of illness, and he was discharged well.

CASE 2

A 23‐year‐old lady, with no prior medical illness presented with fever, headache, vomiting, and diarrhea of 4 days duration. Upon arrival to the hospital, she was in hypovolemic shock with a blood pressure of 60/42 mm Hg and heart rate of 122 beats per minute. She was resuscitated with graded crystalloid fluid boluses of 25 mL/kg in total which had resulted in the successful resolution of hypotension. Initial full blood count revealed leukopenia (3.38 × 109/L) and thrombocytopenia (109x109/L). Clinical suspicion of dengue fever was suspected and a rapid NS‐1 antigen (SD Bioline Dengue Duo kit) was requested and shown to be positive. She was admitted and noted to have a persistent fever lasting to day 8 of illness (Figure 3). On day 6 of illness, her temperature was maximal at 40°C. Serial blood investigations were undertaken (Table 2) which showed a threefold increase in the liver function tests. The serum ferritin level was also markedly elevated (38 068 mcg/L), whereas triglyceride and fibrinogen levels were within the normal range (Table 2). A clinical suspicion of HLH was suspected as the HScore was 200 with HLH probability of 88%. Hence, she was started on intravenous dexamethasone 10 mg/m2/d. A bone marrow aspiration and trephine biopsy was performed which revealed a hypocellular marrow with hemophagocytic activity (Figure 4).
Figure 3

Temperature trend of Case 2

Table 2

Laboratory results of Case 2

Day of illness
D4D5D6D7D8D9D10D11D12D13D14
Hemoglobin (g/L) [12‐15]11.312.912.212.912.010.810.3109.79.89.9
Hematocrit [36‐46]33.437343533292928282829
White cell (×109/L) [4‐10]3.383.62.35.510.611.213.211.912.313.012.0
Platelet (×109/L) [150‐410]10990665996121187252304378450
ALT (U/L) [5‐33]212767175344281248271243234176
AST (U/L) [5‐32]43672195279193981871621259657
LDH (U/L) [135‐214]29633882218081964168113961148961687575
Ferritin (μg/L) [13‐150]38 06858 85560 34841 8436775
Fibrinogen (g/L) [2.2‐3.9]1.82.11.71.4
Triglyceride (mmol/L) [1.7‐2.3]1.51.11.42.2
Creatinine (μmol/L) [44‐80]6757575150423945
Figure 4

Bone marrow aspirates examination showed a hypocellular marrow with hemophagocytic activity

Temperature trend of Case 2 Laboratory results of Case 2 Bone marrow aspirates examination showed a hypocellular marrow with hemophagocytic activity Her fever resolved 3 days following administration of dexamethasone (day 9 of her illness), along with improvements in liver enzymes and serum ferritin levels. Dexamethasone was stopped on day 13. Thereafter, she made a full recovery.

DISCUSSION

Dengue virus is the cause of dengue infection which belongs to the genus flavivirus within the Flaviviridae family. The dengue virus (DENV) has 4 distinct serotypes, namely DENV‐1, DENV‐2, DENV‐3, and DENV‐4. There are nearly 50 million cases of dengue infection and 500,000 individuals are hospitalized with dengue hemorrhagic fever each year, mainly in tropical countries. Severe dengue is the leading cause of death related to dengue infection; caused by severe hemorrhage, plasma leakage, fluid accumulation, respiratory distress, or organ impairment. A local study showed a significant number of DENV‐2 infected patients developed severe dengue more frequently as compared to other serotypes. Patients with severe dengue are also at risk of developing secondary HLH which would further contribute to the high mortality. HLH is a hyperinflammatory condition which is characterized by macrophage activation with phagocytosis of blood cells in the bone marrow and cytokine storm, leading to organ dysfunction and death. , , Viral infections are a common trigger of HLH but the exact mechanisms by which viruses are implicated in the pathogenesis of HLH remain unproven. It was postulated that viruses, as potent modulators of immune system, may contribute to the development of HLH through evasion of interference with cytokine balance, immune recognition, and inhibition of apoptotic pathways. HLH in dengue infection remains a diagnostic challenge and can be misdiagnosed as sepsis because of the nonspecific, overlapping clinical features. The diagnosis of HLH requires fulfillment of at least 5 of the 8 criteria as listed: fever, splenomegaly, cytopenia affecting at least 2 of 3 lineages in peripheral blood, ferritin ≥ 500 μg/L, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis in bone marrow or spleen or lymph nodes, low or absent NK‐cell activity, and high level of soluble CD25. Markedly raised serum ferritin level is strongly associated with HLH, and a cutoff value of > 10,000mcg/L was 90% sensitive and 96% specific for HLH. Hyperferritinemia observed in patients with dengue infection is suggestive of highly active disease with increased risk of hyperinflammation and coagulation disturbances. This emphasizes the need for closer monitoring in dengue virusinfected patients with hyperferritinemia. In case 1, HLH was suspected due to resurgence of high‐grade fever after an initial defervescence, along with the raised serum ferritin level and abrupt thrombocytopenia. Persistence of fever beyond 7 days and worsening liver functions also suggested the possibility of HLH, as seen in case 2. Both patients were started on intravenous dexamethasone in view of high clinical suspicion of HLH and responded well with resolution of fever and improving blood parameters. Therefore, early recognition and diagnosis of dengue‐associated HLH and prompt intervention could have contributed to the favorable outcome in these patients. Both patients described in this case report underwent bone marrow biopsy which showed presence of hemophagocytic activity. These findings were supportive of our diagnosis of hemophagocytic lymphohistiocytosis due to dengue infection. The typical histopathological findings of HLH include diffuse accumulation of lymphocytes and mature macrophages, which occasionally exhibit hemophagocytosis. Of note, the sensitivity and specificity of hemophagocytosis for HLH were 83% and 60% respectively. Therefore, a negative initial bone marrow specimen should not delay diagnosis and initiation of HLH treatment. Corticosteroids are often used as an initial agent in the treatment of HLH, whereas other treatment options include etoposide, intravenous immunoglobulin, and intrathecal methotrexate. Treatment of severe EBV‐associated HLH with dexamethasone and etoposide had resulted in a reduction of mortality among patients who received treatment. , There are numerous published case reports of successful outcome in the use of dexamethasone in patients with severe dengue that developed HLH. , Randomized control trials on the use of such agents in the treatment of dengue fever complicated by HLH are urgently needed in evaluating its role in management.

CONCLUSION

HLH is an uncommon but severe complication of dengue infection. Clinicians should have a high index of suspicion of HLH in patients with dengue infection especially if there is a recurrent fever after defervescence or persistent fever >7 days, any cytopenias, or extremely high serum ferritin. Early recognition of this condition and use of corticosteroids is a major contributing factor in improving clinical outcome.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

CYC: preparation of the manuscript and involved in management of the patient. MR, MZ: data curation, assisted in writing manuscript, and involved in patient care. ELCO: proofread and correction of the final manuscript.

ETHICAL APPROVAL

Written informed consent was obtained from the patients for publication of this case report. A copy of the written consent is available for review by the Editor‐in‐Chief of this journal.
  1 in total

1.  A Fatal Case of Dengue-Associated Hemophagocytic Lymphohistiocytosis and Retroperitoneal Hematoma in a Patient With Autoimmune Hemolytic Anemia.

Authors:  Chee Yik Chang
Journal:  Cureus       Date:  2021-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.